SILK ROAD MEDICAL INC (SILK) Stock Price, Forecast & Analysis
USA - NASDAQ:SILK - US82710M1009 - Common Stock
SILK Key Statistics, Chart & Performance
The current stock price of SILK is 27.49 USD. In the past month the price increased by 1.36%. In the past year, price increased by 74.98%.
SILK Latest News, Press Relases and Analysis
SILK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| RMD | RESMED INC | 24.94 | 36.03B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B | ||
| STE | STERIS PLC | 24.71 | 23.21B |
Related stock screener links
About SILK
Company Profile
Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 474 full-time employees. The company went IPO on 2019-04-04. The firm has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. The company manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Company Info
SILK ROAD MEDICAL INC
1213 Innsbruck Dr
Sunnyvale CALIFORNIA 94089 US
CEO: Erica J. Rogers
Employees: 474
Phone: 16505669060
SILK ROAD MEDICAL INC / SILK FAQ
What does SILK do?
Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 474 full-time employees. The company went IPO on 2019-04-04. The firm has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. The company manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
What is the current price of SILK stock?
The current stock price of SILK is 27.49 USD. The price decreased by -0.04% in the last trading session.
Does SILK stock pay dividends?
SILK does not pay a dividend.
What is the ChartMill technical and fundamental rating of SILK stock?
SILK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is SILK ROAD MEDICAL INC (SILK) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SILK.
What is SILK ROAD MEDICAL INC worth?
SILK ROAD MEDICAL INC (SILK) has a market capitalization of 1.12B USD. This makes SILK a Small Cap stock.
Can you provide the upcoming earnings date for SILK ROAD MEDICAL INC?
SILK ROAD MEDICAL INC (SILK) will report earnings on 2024-11-06, after the market close.
SILK Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SILK. When comparing the yearly performance of all stocks, SILK is one of the better performing stocks in the market, outperforming 90.01% of all stocks.
SILK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SILK. SILK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SILK Financial Highlights
Over the last trailing twelve months SILK reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS decreased by -2.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.96% | ||
| ROE | -36.55% | ||
| Debt/Equity | 0.49 |
SILK Forecast & Estimates
13 analysts have analysed SILK and the average price target is 22.54 USD. This implies a price decrease of -18% is expected in the next year compared to the current price of 27.49.
For the next year, analysts expect an EPS growth of -3.77% and a revenue growth 16.35% for SILK